New Treatments in Noninfectious Uveitis 1st Edition by E Miserocchi, G Modorati, CS Foster, F Bandello ISBN 3805599862 9783805599863

New Treatments in Noninfectious Uveitis 1st Edition by E Miserocchi, G Modorati, CS Foster, F Bandello – Ebook PDF Instant Download/Delivery: 3805599862, 9783805599863
Full download New Treatments in Noninfectious Uveitis 1st Edition after payment

Product details:

ISBN 10: 3805599862 
ISBN 13: 9783805599863
Author: E Miserocchi, G Modorati, CS Foster, F Bandello

New Treatments in Noninfectious Uveitis 1st Table of contents:

1. The Philosophy of Treatment of Uveitis: Past, Present and Future
2. Abstract
3. References
4. The Gold Standard of Noninfectious Uveitis: Corticosteroids
5. Abstract
6. When May We Use Corticosteroid Therapy in Noninfectious Uveitis?
7. Pharmacology
8. Preparations and Administration
9. Topical Preparations and Administration Route
10. Iontophoresis Technology
11. Regional Preparations and Administration Routes
12. Summary
13. Technique, Indications and Contraindications of Intravitreal Corticosteroids
14. Systemic Preparations
15. Adjunctive therapy
16. Systemic CS administration
17. Practical Therapeutic Utilization
18. General Considerations
19. Therapeutic Strategies
20. Adverse Effects of Corticosteroid Therapy
21. Ocular Side Effects of Corticosteroid Treatment
22. General Considerations
23. Intraocular Pressure Elevation
24. Corticosteroid-Induced Cataract Formation
25. Nonocular Side Effects of Corticosteroid Treatment
26. High-Risk Group of Patients
27. Pregnancy
28. Use in Lactation
29. Use in Children
30. Use in the Elderly
31. Conclusion
32. References
33. Corticosteroid-Sparing Agents: Conventional Systemic Immunosuppressants
34. Abstract
35. Indications & Dosage
36. Alkylating Agents
37. Cyclophosphamide (Cytoxan®, Neosar®)
38. History and Source
39. Pharmacology
40. Clinical Pharmacology
41. Therapeutic Value
42. Dosage and Side Effects
43. Systemic Immunosuppressive Therapy for Eye Disease Study
44. Chlorambucil
45. History and Source
46. Pharmacology
47. Clinical Pharmacology
48. Therapeutic Value
49. Dosage and Side Effects
50. Systemic Immunosuppressive Therapy for Eye Disease Study
51. Antimetabolites
52. Methotrexate
53. History and Source
54. Pharmacology
55. Clinical Pharmacology
56. Therapeutic Value
57. Dosage and Side Effects
58. Systemic Immunosuppressive Therapy for Eye Disease Study
59. Azathioprine
60. History and Source
61. Pharmacology
62. Clinical Pharmacology
63. Therapeutic Effects
64. Dosage and Side Effects
65. Systemic Immunosuppressive Therapy for Eye Disease Study
66. Antibiotics
67. Cyclosporine
68. History and Source
69. Pharmacology
70. Clinical Pharmacology
71. Therapeutic Value
72. Dosage and Side Effects
73. Systemic Immunosuppressive Therapy for Eye Disease Study
74. Major Reactions & Interactions
75. References
76. Corticosteroid-Sparing Agents: New Treatment Options
77. Abstract
78. Systemic Steroid-Sparing Agents
79. Antimetabolites
80. Alkylating Agents
81. T Cell Inhibitors
82. Biologic Anti-Inflammatory Agents
83. Local Steroid-Sparing Agents
84. References
85. Mycophenolate Mofetil Use in the Treatment of Noninfectious Uveitis
86. Abstract
87. Mycophenolate Mofetil in the Treatment of Pediatric Uveitis
88. Treatment Algorithm(s) in the Use of Mycophenolate Mofetil in Uveitis Patients
89. References
90. Anti-Tumor Necrosis Factor-α Agents in Noninfectious Uveitis
91. Abstract
92. Tumor Necrosis Factor-α
93. Anti-TNF-α Agents
94. Etanercept
95. Infliximab
96. Adalimumab
97. New TNF-α Blockers
98. Anti-TNF-α Agents: Treatment Indications for Use
99. Behçet’s Disease-Associated Uveitis
100. Spondyloarthropathies and B27-Associated Uveitis
101. Juvenile Idiopathic Arthritis
102. Sarcoidosis
103. Uveitis Associated with Other Conditions
104. Adverse Events
105. Infections
106. Demyelination
107. Others
108. Paradoxical Adverse Events
109. Ocular Surgery
110. ‘Switching’ Anti-TNF-α Agents
111. Future Directions
112. Conclusions
113. References
114. New Biologic Drugs: Anti-Interleukin Therapy
115. Abstract
116. Introduction
117. Background Information: Interleukins and Uveitis
118. What Is a Biologic Agent?
119. How Safe Are Anti-Interleukin Agents?
120. Possible Indications for Anti-Interleukin Treatment
121. Interdisciplinary Approach in a Specialized Medical Care Unit
122. Anti-IL-1 Receptor Antagonist (Anakinra)
123. Anti-IL-2 Receptor Antibody (Daclizumab)
124. Anti-IL-15 Antibody (HuMax-IL15)
125. Anti-IL-6 Receptor Antibody (Tocilizumab)
126. Anti-IL-17 Antibody (AIN457)
127. Final Remarks
128. References
129. Interferon-α Therapy in Noninfectious Uveitis
130. Abstract
131. Mechanisms and Pharmacology
132. Experimental Work
133. Clinical Effects
134. Side Effects
135. Conclusion
136. References
137. Rituximab for Noninfectious Uveitis
138. Abstract
139. Rituximab: General Considerations
140. The CD20 Antigen
141. Rituximab in Systemic Autoimmune Diseases
142. Rituximab in Inflammatory Eye Diseases
143. Uveitis
144. Uveitis in Behçet’s Disease
145. Uveitis in Children with Juvenile Idiopathic Arthritis
146. Uveitis Associated with Intraocular Lymphoma
147. Treatment of Other Ocular Inflammatory Diseases
148. Inflammation of the Sclera
149. Ocular Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
150. Dry Eye and Sjögren’s Syndrome
151. Safety of Rituximab
152. Retreatment
153. Conclusions
154. References
155. Intravitreal Injection Therapy in the Treatment of Noninfectious Uveitis
156. Abstract
157. The Structure of the Eye
158. Drug Delivery to the Posterior Segment
159. Intravitreal Injection
160. Intravitreal Injection Technique
161. Immunomodulators
162. Intraocular Methotrexate
163. Tacrolimus (FK506)
164. Anti-VEGF Drugs
165. Ranibizumab
166. Bevacizumab
167. Tumor Necrosis Factor -α Blockers
168. Adalimumab
169. Infliximab
170. Corticosteroids
171. Intravitreal Triamcinolone Acetonide
172. Nonsteroidal Anti-Inflammatory Agents
173. References
174. Corticosteroid Intravitreal Implants
175. Abstract
176. Pharmacology of Steroids
177. Design and Pharmacology of Steroid Implants
178. Clinical Efficacy and Tolerability of Steroid Intravitreal Implants
179. Ocular Implants vs. Systemic Anti-Inflammatory Therapy
180. Treatment Paradigm in the Management of Uveitis with Steroid Implants
181. Uveitis with Systemic Disease
182. Uveitis with No Systemic Disease
183. Specific Medical Conditions
184. References
185. New Treatment Options for Noninfectious Uveitis
186. Abstract
187. Pathogenesis
188. Standard Therapies
189. New Agents in the Uveitis Pharmacotherapy: Emerging Drugs
190. Inhibitors of T Cell Activation
191. New Generation of the Calcineurin Inhibitors: Voclosporin
192. Evaluation of Voclosporin Efficacy
193. Potential Risks and Benefits of Voclosporin
194. m-TOR Pathway Modulator: Sirolimus
195. Evaluation of Sirolimus Efficacy
196. Potential Risks and Side Effects of Sirolimus
197. Biologics
198. Inhibitors of IL-1: Rilonacept, Canakinumab, Anakinra, and Gevokizumab
199. Rilonacept (ARCALYST)
200. Canakinumab (Ilaris)
201. Anakinra (Kineret)
202. Gevokizumab
203. Inhibitor of IL-6: Tocilizumab
204. The Immune System as a Potential Target of New Drugs
205. Novel Drug Delivery Systems
206. Nanoparticles
207. Iontophoresis for Uveitis
208. Application in Uveitis and Ocular Inflammatory Diseases

People also search for New Treatments in Noninfectious Uveitis 1st:

    
non-infectious uveitis
    
non infectious uveitis treatment guidelines
    
non-infectious uveitis symptoms
    
what is the new treatment for eye uveitis
    
chronic non-infectious uveitis

Tags: E Miserocchi, G Modorati, CS Foster, F Bandello, Noninfectious Uveitis